Floatz logo

Ampreloxetine

Hypotension, Orthostatic

Theravance BiopharmaSmall moleculePhase 2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Hypotension, Orthostatic cohort.

Asset / SponsorPhaseRating
LEVODOPA
Julien Bally
Phase 1/2CCC
carbidopa
Julien Bally
Phase 1/2CCC
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Jonathann Kuo, MD
Phase 1CC

Same molecule, other indications

Ampreloxetine is also rated in:

primary orthostatic hypotensionDormant
CCC
Indicative ·
54 / 100
View asset →
multiple system atrophyDormant
CCC
Indicative ·
51 / 100
View asset →
pure autonomic failureDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →